Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.650 +0.020 (+0.30%)

Delayed Quote Updated: 3:58 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 07, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

May 07, 2025

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Myriad Genetics's Earnings: A Preview ↗

May 05, 2025

Via Benzinga

Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%

May 06, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue...

Via StockStory

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 06, 2025

Via Benzinga

Which stocks are moving after the closing bell on Tuesday? ↗

May 06, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

May 06, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

What To Expect From Myriad Genetics’s (MYGN) Q1 Earnings

May 05, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after the bell. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

3 Unprofitable Stocks Walking a Fine Line

May 02, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

1 Unprofitable Stock to Target This Week and 2 to Be Wary Of

May 01, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

April 30, 2025

More than half say genetic testing for mental health medications could reduce concerns

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

April 29, 2025

Management will participate in two upcoming investor healthcare conferences

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

April 25, 2025

Podium presentation showcases the clinical application of Precise™ MRD

From Myriad Genetics, Inc.

Via GlobeNewswire

3 Healthcare Stocks That Concern Us

April 25, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

April 21, 2025

Study published in the Journal of Clinical Psychopharmacology

From Myriad Genetics, Inc.

Via GlobeNewswire

Demystifying Myriad Genetics: Insights From 10 Analyst Reviews ↗

April 17, 2025

Via Benzinga

Myriad Genetics Announces Inducement Awards

April 08, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

April 07, 2025

From Myriad Genetics, Inc.

Via GlobeNewswire

10 Analysts Assess Myriad Genetics: What You Need To Know ↗

April 01, 2025

Via Benzinga

Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 01, 2025

Via Benzinga

Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 01, 2025

Via Benzinga

1 Small-Cap Stock on Our Watchlist and 2 to Avoid

March 20, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

March 19, 2025

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Via StockStory

Topics Artificial Intelligence

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?

March 17, 2025

Myriad Genetics’s stock price has taken a beating over the past six months, shedding 65.1% of its value and falling to $9.99 per share. This might have investors contemplating their next move.

Via StockStory

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗

March 12, 2025

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Via Benzinga

Why Are Myriad Genetics (MYGN) Shares Soaring Today

March 12, 2025

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook...

Via StockStory

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

March 12, 2025

Via Benzinga

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

March 11, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.